Nyxoah (NASDAQ:NYXH) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Nyxoah (NASDAQ:NYXH) in a research report released on Wednesday, Benzinga reports. HC Wainwright currently has a $18.00 price target on the stock. HC Wainwright also issued estimates for Nyxoah’s Q3 2024 earnings at ($0.50) EPS, Q4 2024 earnings at ($0.49) EPS, FY2024 earnings at ($1.92) EPS, FY2025 earnings at ($1.42) EPS and FY2026 earnings at $0.15 EPS.

NYXH has been the topic of a number of other reports. Cantor Fitzgerald cut their price target on Nyxoah from $18.00 to $17.00 and set an overweight rating on the stock in a report on Wednesday, May 15th. Oppenheimer cut their price target on Nyxoah from $20.00 to $15.00 and set an outperform rating on the stock in a report on Wednesday, May 15th. Finally, Stifel Nicolaus cut their price target on Nyxoah from $27.00 to $19.00 and set a buy rating on the stock in a report on Monday, June 24th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of Buy and an average target price of $17.20.

Nyxoah Trading Up 2.4 %

NYXH opened at $8.54 on Wednesday. The stock’s fifty day moving average is $8.34 and its two-hundred day moving average is $10.62. The company has a market capitalization of $212.99 million, a P/E ratio of -5.21 and a beta of 1.44. Nyxoah has a 52 week low of $4.00 and a 52 week high of $20.00. The company has a quick ratio of 3.70, a current ratio of 3.94 and a debt-to-equity ratio of 0.13.

Nyxoah (NASDAQ:NYXH) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.45) EPS for the quarter, hitting the consensus estimate of ($0.45). The company had revenue of $1.33 million for the quarter, compared to the consensus estimate of $1.20 million. Nyxoah had a negative return on equity of 42.14% and a negative net margin of 843.49%. Analysts forecast that Nyxoah will post -1.72 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Nyxoah stock. Ikarian Capital LLC bought a new position in shares of Nyxoah S.A. (NASDAQ:NYXH) during the 1st quarter, according to its most recent 13F filing with the SEC. The fund bought 50,699 shares of the company’s stock, valued at approximately $684,000.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.